News

Gilead Sciences has expanded its R&D infrastructure with a new 182,000-square-foot facility in Foster City dedicated to inflammation, oncology, and data science.

Research Peptides in Modern Drug Discovery: Quality, Purity, and Sourcing Standards Peptides have been a part of research for many years. The way scientists handle peptides has changed a lot. New methods for making them, better tools to analyze them,...

In recent years, biomarkers have become an essential part of patient evaluation and are driving the overall therapeutic strategy. Accurate molecular profiling of the tumor before any intervention is an essential component of effective treatment planning for stage 4...

The quote said 98.5%. The certificate that arrived nine days later said 96.1%, and it covered a batch that had already gone into a dose-response series. We repeated the work. The reagent cost was trivial; the three weeks were...

Boehringer Ingelheim has joined other pharmaceutical leaders in deploying Owkin's agentic AI scientist, K Pro, to analyze multimodal patient data in oncology and immunology R&D.

The European Medicines Agency has launched a voluntary framework for sharing data from non-animal testing methods to build regulatory confidence and refine drug development.

Novartis has signed a landmark agreement with South Korean biopharmaceutical firm Alteogen, potentially valued at up to $3.22 billion, for the development and commercialisation of subcutaneous drug formulations powered by Alteogen's proprietary ALT-B4 technology. A Multi-Option Agreement Targeting Subcutaneous Formulation The...